Forxiga® (Dapagliflozin)
A19-53 - Dapagliflozin - Nutzenbewertung gemäß § 35a SGB V - Version 1.0
Dapagliflozin -Fotos und -Bildmaterial in hoher Auflösung – Alamy
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy | Cardiovascular Diabetology | Full Text
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice - ScienceDirect
Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes - Clinical Trials Arena
Dapagliflozin May Reduce the Onset of Type 2 Diabetes - Beyond Type 2
Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes | tctmd.com
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial - The Lancet
Pharmakovigilanz: Gliflozin-Nutzen überwiegt das Risiko
Add on Dapagliflozin exhibits inconsequential antidiabetic effect in kids with type 2 diabetes
Dapagliflozin zur Therapie des Typ-2-Diabetes - 03 - 2013 - Heftarchiv - AMT
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
IJMS | Free Full-Text | Dapagliflozin Prevents NOX- and SGLT2-Dependent Oxidative Stress in Lens Cells Exposed to Fructose-Induced Diabetes Mellitus
FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations | DAIC
Dapagliflozin treatment for type 2 diabetes mellitus patients with a history of cardiovascular disease - Media Centre | EASD
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study - The Lancet Diabetes & Endocrinology
Type 2 Diabetes: Glenmark to launch Teneligliptin + Dapagliflozin FDC for T2 diabetes in adults, Health News, ET HealthWorld
10 Jahre Dapagliflozin für Typ-2-Diabetes, HFrEF und CKD
Typ-2-Diabetes und Herz-Kreislauf-Risiko: Dapagliflozin hat positive Effekte auch in der kardiovaskulären Primärprävention
forxiga® 10 mg Filmtabletten 98 St - shop-apotheke.com
Typ-2-Diabetes bei Kindern und Jugendlichen: Dapagliflozin ist eine weitere Option zur oralen Therapie für junge Menschen
FDA erweitert Zulassung: Dapagliflozin künftig bei Herzinsuffizienz – auch ohne Diabetes
Healthcare | Free Full-Text | Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
